Ajanta Pharma Limited received final approval from US FDA and launched Omeprazole and Sodium Bicarbonate Capsules in the US market, through its wholly owned subsidiary Ajanta Pharma USA Inc.
It is a bioequivalent prescription generic version of Zegerid®1 and the company has launched the product in 2 strengths 20mg/1100mg & 40mg/1100mg capsules.
Omeprazole and Sodium Bicarbonate Capsules is part of an ever-growing portfolio of products that Ajanta has developed for the US market. In total, Ajanta has 26 Abbreviated New Drug Application (ANDA) of which it has final approvals for 11 ANDAs; tentative approvals for 1 ANDA; and 14 ANDAs are under review with US FDA.
